期刊
JOURNAL OF HEMATOLOGY & ONCOLOGY
卷 5, 期 -, 页码 -出版社
BMC
DOI: 10.1186/1756-8722-5-10
关键词
China; Allo-HSCT; Haploidentical; Relapse; GVHD; Elderly patients
资金
- National Natural Science Foundation of China [30971292]
- Ministry of Education of China [20110001110039]
- Natural Science Foundation of Beijing [7122193]
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective and sometimes the only curative therapy for patients with certain hematological diseases. Allo-HSCT has been practiced in China for approximately 30 years, and great improvements have been made within the past decade, particularly in fields such as the haploidentical HSCT system, strategies to overcome relapse and GVHD, and modified HSCT for elderly patients. This review will describe the current situation and provide a prospective of these unique aspects of Allo-HSCT in China.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据